Edition:
United Kingdom

Advanced Accelerator Applications SA (AAAP.OQ)

AAAP.OQ on NASDAQ Stock Exchange Global Select Market

81.53USD
15 Dec 2017
Change (% chg)

$-0.06 (-0.07%)
Prev Close
$81.59
Open
$81.63
Day's High
$81.72
Day's Low
$81.53
Volume
145,435
Avg. Vol
157,685
52-wk High
$81.74
52-wk Low
$23.50

Chart for

About

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer.... (more)

Overall

Beta: --
Market Cap(Mil.): $3,115.66
Shares Outstanding(Mil.): 21.99
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Advanced Accelerator Applications Announces Commencement Of Novartis Tender Offer

* ADVANCED ACCELERATOR APPLICATIONS ANNOUNCES COMMENCEMENT OF NOVARTIS TENDER OFFER

07 Dec 2017

BRIEF-Advanced Accelerator Applications Board Recommends $3.9 Bln All Cash Tender Offer By Novartis

* ADVANCED ACCELERATOR APPLICATIONS BOARD OF DIRECTORS RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS

05 Dec 2017

BRIEF-Advanced Accelerator Applications reports qtrly loss per share EUR​ ‍0.26

* Advanced Accelerator Applications reports 39% sales growth for third quarter 2017

17 Nov 2017

Novartis picks Centerview to explore sale of dermatology unit: sources

LONDON/FRANKFURT Swiss drugmaker Novartis is working with Centerview to review options for its dermatology business, including a possible sale, as it trims non-core assets, two sources familiar with the matter told Reuters.

02 Nov 2017

Novartis picks Centerview to explore sale of dermatology unit -sources

LONDON/FRANKFURT, Nov 2 Swiss drugmaker Novartis is working with Centerview to review options for its dermatology business, including a possible sale, as it trims non-core assets, two sources familiar with the matter told Reuters.

02 Nov 2017

Novartis to buy French cancer specialist AAA for $3.9 billion

ZURICH Novartis has agreed to buy French-based Advanced Accelerator Applications (AAA) for $3.9 billion, giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.

30 Oct 2017

UPDATE 3-Novartis to buy French cancer specialist AAA for $3.9 bln

* French company had first-half sales of $78 mln (Adds Breakingviews link, further detail on Novartis cancer drugs)

30 Oct 2017

Novartis to buy France's Advanced Accelerator for $3.9 billion

ZURICH Swiss drugmaker Novartis on Monday offered to buy France's Advanced Accelerator Applications (AAA) in a $3.9 billion (2.97 billion pounds) cash deal to strengthen the oncology portfolio at the world's biggest maker of prescription medicines.

30 Oct 2017

BRIEF-Advanced Accelerator announces $3.9 bln all cash proposed tender offer by Novartis

* Advanced accelerator applications announces $3.9 billion all cash proposed tender offer by Novartis

30 Oct 2017

BRIEF-Advanced Accelerator announces European approval of lutetium oxodotreotide for gastroenteropancreatic neuroendocrine tumors

* Advanced Accelerator Applications announces European approval of lutetium (177lu) oxodotreotide (lutathera®) for gastroenteropancreatic neuroendocrine (gep-net) tumors

29 Sep 2017

Earnings vs. Estimates